Single-blinded, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes

The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes. The main questions it aims to answer are:
* Is the disease better controlled when the treatment prescribed is based on the participant's pharmacogenetic profile?
* What medical problems do participants experience while taking the treatment?
Participants will:
* Take the treatment described according to the Summary of Product Characteristics (SmPC).
* Visit the clinic once every 12 weeks for checkups and tests.
* Keep a diary of their symptoms to inform the Investigator.

Start Date01 Apr 2025

Sponsor / Collaborator-

NCT06858436

/ Not yet recruitingPhase 4IIT

The Role of SGLT2 Inhibitors in Stroke-reperfusion Injury:A Multi-Center, Randomized, Open-Label, Controlled Trial

Background:
Reperfusion therapies, including intravenous rt-PA and mechanical thrombectomy, significantly improve outcomes in acute ischemic stroke. However, these interventions also increase the risk of hemorrhagic transformation and malignant edema. Preclinical studies have demonstrated that Canagliflozin, an SGLT2 inhibitor, reduces astrocyte swelling and brain edema in a transient middle cerebral artery occlusion (tMCAo) model. While SGLT2 inhibitors have shown neuroprotective effects in the acute phase of ischemic stroke, their potential to mitigate hemorrhagic transformation and malignant edema following reperfusion therapy in humans remains unexamined.
Aims:
This study aims to evaluate the effect of SGLT2 inhibitors on hemorrhagic transformation and malignant edema in patients undergoing reperfusion therapy for acute ischemic stroke.
Methods:
This is a multi-center, randomized, open-label, controlled study enrolling ischemic stroke patients aged 18 years or older who meet predefined inclusion and exclusion criteria. Participants will be randomized to receive Canagliflozin 100 mg once daily for 14 days or no additional treatment before undergoing mechanical thrombectomy. Clinical data collection will include baseline demographics, medical and medication history, NIHSS scores at admission and 24 hours post-reperfusion, stroke subtype, modified Thrombolysis in Cerebral Infarction (TICI) scores, laboratory results, and modified Rankin Scale (mRS) scores at discharge and 3 months post-stroke.
The primary outcome is to assess the association between Canagliflozin use and the severity of hemorrhagic transformation and malignant edema. Hemorrhagic transformation will be classified using the Heidelberg criteria, and malignant edema will be defined as a midline shift of ≥5 mm. Brain imaging, including CT scans at 24 hours post-intervention and additional scans as clinically indicated, will be reviewed by blinded radiologists. Brain MRA will also be performed to assess infarct size and edema progression.
Importance:
This study aims to explore the potential for repurposing SGLT2 inhibitors as a therapeutic strategy in acute ischemic stroke. If Canagliflozin is shown to reduce hemorrhagic transformation and malignant edema, it could offer a novel adjunctive treatment to improve patient outcomes following reperfusion therapy.

Start Date20 Mar 2025

Sponsor / Collaborator

Taichung Veterans General Hospital

NCT06528405

/ RecruitingPhase 2IIT

The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

Acute kidney disease (AKD) happens between 7 and 90 days after an initial kidney injury (AKI). This period is crucial because it can determine whether the condition worsens into chronic kidney disease (CKD). Despite knowing this, there is no proven treatment to improve outcomes for people with AKD.
Recent studies have shown that drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors can slow down the worsening of chronic kidney disease, help with heart failure, and reduce the risk of death. Now, researchers are looking into whether these drugs can also help prevent acute kidney injury (AKI) and improve outcomes for AKD patients.
Our project will explore the use of SGLT2 inhibitors in patients with AKD, with the belief that these drugs can safely reduce the amount of protein (albumin) in the urine and improve kidney health. To address this, investigators plan to conduct a large, multicenter study in Taiwan. This study will be randomized and placebo-controlled, meaning some patients will receive the SGLT2 inhibitors while others will receive a placebo (a harmless, inactive substance). Investigators will include AKD patients with and without diabetes, focusing on reducing the protein in their urine and monitoring for any serious side effects.
The goal of this trial is to provide strong evidence on whether SGLT2 inhibitors can be an effective treatment for AKD. If successful, this could offer a new strategy to prevent the progression from AKI to CKD and improve the health and outcomes of patients with kidney disease.

Start Date21 Nov 2024

Sponsor / Collaborator

National Taiwan University Hospital

[+2]

100 Clinical Results associated with Canagliflozin Hemihydrate

100 Translational Medicine associated with Canagliflozin Hemihydrate

100 Patents (Medical) associated with Canagliflozin Hemihydrate

2,539

Literatures (Medical) associated with Canagliflozin Hemihydrate

01 Jun 2025·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

SGLT2i delays c-Myc-induced HCC progression via targeting mTOR

Article

Author: Du, Weixing ; Ke, Jing ; Liu, Zhixin ; Yu, Juan ; Qiu, Zhenpeng ; Qu, Xinyang ; An, Xiaotong ; Liu, Danwen ; Rao, Huiling ; Li, Wanrong ; Li, Shan ; You, Lei ; Xie, Jin ; Tian, Lin ; Jia, Jie

BACKGROUND:

Hepatocellular carcinoma (HCC) stands as a primary malignant liver tumor characterized by metabolic reprogramming. The oncogene c-Myc exerts substantial influence by driving the transcription of numerous genes. Empagliflozin (EMPA), a sodium-glucose cotransporter-2 inhibitor (SGLT2i), is widely used in the treatment of type 2 diabetes and has recently attracted attention for its potential anti-cancer effects. This study aims to unravel the complex interplay among c-Myc, EMPA, and the mammalian target of rapamycin (mTOR) in HCC development and progression.

METHODS:

HCC induction in mice utilized high-pressure hydrodynamic transfection of the c-Myc plasmid. QPCR and immunohistochemistry experiments were performed to detect the expression of SGLT2 in HCC tissues. In vivo experiments were conducted to corroborate the upregulation of SGLT2 following c-Myc transfection. In invo and vitro investigations were conducted to evaluate the anti-cancer effects of two SGLT2i: EMPA and canagliflozin (CANA). Network pharmacology, molecular docking analyses, CETSA experiments, and additional western blot experiments were used to reveal EMPA's interaction inhibition with mTOR.

RESULTS:

The study identified an increase in SGLT2 expression in HCC tissues as a result of c-Myc overexpression. In vitro experiments confirmed the upregulation of SGLT2 following c-Myc transfection. Notably, the administration of SGLT2i effectively curtailed liver cancer progression, and reduced hepatic fat accumulation in mice. EMPA exhibited significant suppression of cell proliferation in c-Myc-transfected cells. In vitro experiments unveiled EMPA's interaction and with inhibition the activation of mTOR.

CONCLUSION:

Our study highlights EMPA's potential as a therapeutic agent in delaying the development and progression of HCC.

24 May 2025·Journal of biomolecular structure & dynamics

Identification of approved drugs with ALDH1A1 inhibitory potential aimed at enhancing chemotherapy sensitivity in cancer cells: an in-silico drug repurposing approach

Article

Author: Paul, Sanjay Kumar ; Guendouzi, Abdelmadjid ; Banerjee, Agniswar ; Guendouzi, Abdelkrim ; Haldar, Rajen

The aldehyde dehydrogenase 1A1 (ALDH1A1) also known as retinal dehydrogenase, is an enzyme normally involved in the cellular metabolism, development and detoxification processes in healthy cells. However, it's also considered a cancer stem cell marker and its high levels of expression in several cancers, including breast, lung, ovarian, and colon cancer have been associated with poor prognosis and resistance to chemotherapy. Given its crucial role in chemotherapy resistance by detoxification of chemotherapeutic drugs, ALDH1A1 has attracted significant research interest as a potential therapeutic target for cancer. Though a few synthetic inhibitors of ALDH1A1 have been synthesized and their efficacy has been proved in-vitro and in-vivo studies, none of them have passed clinical trials so far. In this scenario, we have performed an in-silico study to verify whether any of the already approved drugs used for various purposes has the ability to inhibit catalytic activity of ALDH1A1, so that they can be repurposed for cancer therapy. Keeping in mind the feasibility of repurposing in a larger population we have selected the approved drugs from five widely used drug categories such as antibiotic, antiviral, antifungal, anti diabetic and antihypertensive for screening. Computational techniques like molecular docking, molecular dynamics simulations and MM-PBSA binding energy calculation have been used in this study to screen the approved drugs. Based on the logical analysis of results, we propose that three drugs - telmisartan, irbesartan and maraviroc can inhibit the catalytic activity of ALDH1A1 and thus can be repurposed to increase chemotherapy sensitivity in cancer cells.

01 Apr 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

The diabetes medication Canagliflozin attenuates alcoholic liver disease by reducing hepatic lipid accumulation via SIRT1-AMPK-mTORC1 signaling pathway

Article

Author: Luo, Gang ; Su, Hao ; Yang, Xuping ; Dong, Wenjie ; Chen, Lei ; Zhang, Liaoyun ; Liu, Qinhui ; Li, Xiangyu ; Huang, Yilan ; Li, Qiuyu

BACKGROUND AND AIMS:

Chronic consumption of large amounts of alcohol can lead to hepatic lipid accumulation and mitochondrial oxidative stress, resulting in alcoholic liver disease (ALD). Canagliflozin (Cana), an oral antidiabetic drug, regulates blood glucose by inhibiting sodium-glucose cotransporter-2 in renal tubulars, which also improves lipid metabolism and alleviates oxidative stress in hepatocyte. This study aims to determine the therapeutic effects of Cana on alcoholic liver injury and to explore the mechanistic pathways involved.

METHODS:

C57BL/6J male mice at 8 weeks were used to construct a model of alcoholic fatty liver disease using the chronic-plus-binge alcohol feeding model. Primary hepatocytes and AML12 cell lines were used as in vitro models. The effects and mechanisms of Cana on alcoholic liver injury were investigated by using immunofluorescence, ELISA, H&E and Oil Red O staining, RT-PCR, and western blotting analysis.

RESULTS:

Cana treatment reduced hepatic lipid accumulation, decreased glutathione and TNF-α levels, alleviated oxidative stress and inflammation. Mechanistic studies revealed that Cana reduced FAS expression in the liver, decreasing hepatic fatty acid synthesis, and increased PPARα expression, promoting fatty acid oxidation. Additionally, Cana increased mitochondrial content and promoted mitophagy. These effects were mediated by the SIRT1-AMPK-mTORC1 signaling pathway.

CONCLUSIONS:

Cana activates the SIRT1-AMPK-mTORC1 signaling pathway, inhibiting alcohol-induced fatty acid synthesis, promoting fatty acid degradation, thereby alleviating alcoholic liver injury.

News (Medical) associated with Canagliflozin Hemihydrate

27 Feb 2025

·firstwordpharma.com

Medicare spending on popular diabetes meds jumps over 350% in five years

Medicare Part D spending on leading diabetes medications has reached unprecedented levels, with expenditure skyrocketing from $7.7 billion in 2019 to $35.8 billion in 2023 — translating to a 364% increase over the five-year period, according to newly released data.Auditors from the US Department of Health and Human Services' Office of Inspector General (OIG) identified and analysed Medicare Part D data for 10 widely prescribed type 2 diabetes medications, comprising seven GLP-1s and three SGLT-2 inhibitors, across the US and five overseas territories between January 2019 and December 2023. The analysis looked at utilisation metrics and spending patterns, drawing comparisons with metformin as a baseline therapy. GLP-1s lead uptickDuring the audit period, Medicare Part D expenditure for selected drugs totalled $92.8 billion, with six medications exhibiting substantial spending increases, led by GLP-1 products. Spending on Novo Nordisk's Rybelsus (semaglutide) jumped from $366,000 in 2019 to approximately $1.7 billion by 2023 — a 2182% increase — whereas Ozempic (semaglutide) expenditures increased nearly 16-fold from $552 million to $9.2 billion over the same period, with the number of beneficiaries receiving the medication rising by 929%. Meanwhile, Eli Lilly's Mounjaro (tirzepatide) showed 1541% spending growth in just its second year of coverage.The OIG noted that given a number of the medicines are commonly used off-label for other conditions, notably obesity, their increased use warrants "further inquiry to determine whether…the associated drugs were utilised for medically accepted indications." Meanwhile, TD Cowen analyst Rick Weissenstein suggested that "the data brief may provide ammunition for HHS Secretary Robert Kennedy Jr. and others who see the surge in GLP-1 use as a symptom of 'overmedication' more generally in the US."In contrast, use and spending on Novo's Victoza (liraglutide), Johnson & Johnson's Invokana (canagliflozin), as well as AstraZeneca's Byetta (exenatide) and Bydureon (exenatide extended-release), declined from 2019 to 2023, likely due to the introduction of newer alternatives. In addition, metformin expenditure decreased by 5% from $661 million in 2019 to $628 million in 2023.Spending growth outpaces enrolmentAccording to the analysis, the growth of the selected medications significantly outpaced the 12% increase in Medicare Part D enrolment during the same timeframe, raising concerns about the long-term financial sustainability of the programme. The report suggests that even if spending grows at the minimum observed annual rate of 42% during the five-year period, it could exceed $102 billion for the 10 drugs in 2026. “This substantial increase could have a financial impact on the Medicare programme,” the auditors noted in the report, adding that these findings “may be beneficial to CMS and other policymakers when developing future programme guidance related to these drugs.”Both Ozempic and Rybelsus made it on to the expanded list of medicines selected for the second round of Medicare price negotiations, drawn up by the outgoing Biden administration last month.

26 Feb 2025

·endpts.com

Medicare spending on common diabetes drugs skyrocketed, HHS inspector general finds

The use of a subset of common diabetes drugs skyrocketed in the US Medicare program over a five-year period ending in 2023, according to a new report from the HHS inspector general. The report looked at two widely used classes of diabetes drugs: GLP-1s like Novo Nordisk’s Ozempic, and SGLT-2 drugs including Johnson & Johnson’s Invokana. It found huge growth in the GLP-1 class, with the number of Medicare patients on Ozempic and Rybelsus, another GLP-1 from Novo, rising more than 900% each over that period. The analysis also looked at spending on the products — but with some limitations. Upfront Part D spending on the drugs in 2023 totaled $35.8 billion, with Novo Nordisk’s flagship product Ozempic accounting for more than a quarter of that. But the total is based on list prices and doesn’t include the significant rebates paid by drugmakers, which if included would likely slash the reported amounts. While the number of prescribers of these drugs has grown considerably, who is prescribing the drugs has changed, too. “The prescribers of the diabetes drugs came from a broad range of specialties, primarily internal medicine and endocrinologists, but also including dentists, optometrists, chiropractors, and acupuncturists,” the report found. The agency inspector general projected that if the rate of utilization and spending continues at a similar pace, then annual spending on the same 10 drugs could eclipse $100 billion by 2026, based on list prices and not including rebates. Analysts at TD Cowen said in an investor note Tuesday that the auditing of the drugs was a “minor fundamental risk to GLP-1 uptake.” If anything, they said, it may throw more cold water on an already sluggish effort to expand Medicare’s coverage to include some patients with obesity. “Probably the greatest concern for Novo and Lilly should come in the signal that this report sends as it relates to the government’s cost concerns and its broader stance toward GLP-1s,” the note said.

31 Aug 2024

·www.pharmaceutical-technology.com

Diabetes duration has minimal impact on SGLT2 inhibitor efficacy, as per new analysis

Dr. Jawad Haider Butt shared data demonstrating that a patient’s duration of living with type 2 diabetes does not impact treatment response to Forxiga. Credit: Photo Nature Travel via Shutterstock. SGLT2 inhibitors show significant promise in the treatment of heart failure regardless of how long a patient has had type 2 diabetes, as per a new meta-analysis presented at the European Society of Cardiology (ESC) Congress. At the ESC congress, held from 30 August to 2 September, Dr. Jawad Haider Butt, a research fellow at the University of Glasgow’s British Health Foundation Cardiovascular Research Centre, presented data surrounding the use of SGLT2 inhibitors in patients with heart failure and type 2 diabetes. Despite an industry conception that patients with long-standing type-2 diabetes may be less likely to tolerate and benefit from new treatments, a pooled meta-analysis of AstraZeneca ’s DAPA-HF Phase III trial (NCT03036124) and the Phase III DELIVER trial (NCT03619213), investigating Forxiga (dapagliflozin propanediol), showed that the benefit of Forxiga or Farxiga on the primary outcome was consistent across patients with different type 2 diabetes durations. Furthermore, treatment with Forxiga had a consistent benefit on the worsening of heart failure across type 2 diabetes patients. The pairing of type 2 diabetes and heart failure can be fairly common in patients, explained Butt. Several companies pursue drug development in the two indications due to their overlapping pathogenesis. For example, in 2014, the US Food and Drug Administration first approved Forxiga for the treatment of type 2 diabetes. AstraZeneca has since received approvals for the drug in other metabolic indications, like heart failure with reduced ejection fraction in 2020. Other SGLT2 inhibitor drugs such as Johnson and Johnson’s Invokana (canagliflozin) and Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) are also marketed for the treatment of heart failure and type 2 diabetes in the US. The class of drugs has made a major impact on the heart failure treatment landscape in recent years, amassing significant sales for each company. See Also: J&J targets generalised myasthenia gravis landscape with nipocalimab Pancreatic Islet Transplant Rejection drugs in development, 2024 In a Q2 financial report, Eli Lilly shared that its US revenue from Jardiance reached $428.9m during the quarter. Furthermore, a 2023 annual financial report labelled Forxiga as AstraZeneca’s best-selling drug that year, making $5.96bn in global sales.

Drug ApprovalPhase 3Financial StatementClinical Result

100 Deals associated with Canagliflozin Hemihydrate

External Link

KEGG	Wiki	ATC	Drug Bank
D09592	Canagliflozin Hemihydrate	A10BK02	DB08907

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Type 2 diabetes mellitus with established diabetic nephropathy	Japan	Mitsubishi Tanabe Pharma Corp.	20 Jun 2022
Diabetic Nephropathies	United States	Janssen Pharmaceuticals, Inc.	27 Sep 2019
Diabetes Mellitus, Type 2	United States	Janssen Pharmaceuticals, Inc.	29 Mar 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Failure	Phase 3	United States	Janssen Research & Development LLC	10 Mar 2020
Heart failure with normal ejection fraction	Phase 3	United States	Janssen Research & Development LLC	10 Mar 2020
Heart failure with reduced ejection fraction	Phase 3	United States	Janssen Research & Development LLC	10 Mar 2020
Cardiovascular Diseases	Phase 3	United States	Janssen Research & Development LLC	09 Dec 2009
Cardiovascular Diseases	Phase 3	Argentina	Janssen Research & Development LLC	09 Dec 2009
Cardiovascular Diseases	Phase 3	Australia	Janssen Research & Development LLC	09 Dec 2009
Cardiovascular Diseases	Phase 3	Belgium	Janssen Research & Development LLC	09 Dec 2009
Cardiovascular Diseases	Phase 3	Canada	Janssen Research & Development LLC	09 Dec 2009
Cardiovascular Diseases	Phase 3	Colombia	Janssen Research & Development LLC	09 Dec 2009
Cardiovascular Diseases	Phase 3	Czechia	Janssen Research & Development LLC	09 Dec 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03170518 (CTgov)	Phase 3	Diabetes Mellitus, Type 2	171	placebo+canagliflozin (Placebo)	yefuiiskpi(hzphtylqtf) = oppkkwcczf sipiuwopyl (goihunfnkk, 0.191) View more	-	25 Mar 2025
				Canagliflozin (Canagliflozin 100/300 mg)	yefuiiskpi(hzphtylqtf) = rqqjmanfbu sipiuwopyl (goihunfnkk, 0.194) View more
NCT03436693 (CTgov)	Phase 3	Diabetic Nephropathies	308	Canagliflozin (Canagliflozin 100mg)	xzuudoqhbp = iediguiirx ohfgbybvou (xmlqfuhajn, xvjmrijari - dowhaevrjo) View more	-	15 Jul 2024
				Placebo (Placebo)	xzuudoqhbp = mrleklftkg ohfgbybvou (xmlqfuhajn, tyebkvojra - fchttwahbj) View more
ADA2024	Not Applicable	Diabetes Mellitus, Type 2	-	Canagliflozin 100 mg/d	ooiledlumb(ccgapepsgz) = cfskaqspka xqhniuxokq (juczdhhqci ) View more	-	14 Jun 2024
1340-P (ADA2024)	Not Applicable	Diabetes Mellitus	-	SGLT2i	jwcovvixud(nhtnfzxwcx) = voqouhozjr semihjgexy (uggfslmvvu, 16.6 - 19.7)	Positive	14 Jun 2024
				DPP4i	jwcovvixud(nhtnfzxwcx) = iyestmyhmt semihjgexy (uggfslmvvu, 19.1 - 21.4)
Pubmed \| J Clin Endocrinol Metab	Not Applicable	Vitamin D Deficiency	-	Vitamin D3 supplementation	ntudejvqbo(vgjquuukjn) = VitD3 supplementation decreased the magnitude of canagliflozin-induced changes in 1,25(OH)2D (from −31.3%±4.7% to −9.3%±8.3%; P = .04) qysadotfme (bwpanhihpi ) View more	-	18 Jan 2024
NCT02065791 \| NCT01989754 \| NCT01032629 (CANVAS Program and CREDENCE trial, Pubmed \| Diabetes Obes Metab)	Not Applicable	Diabetes Mellitus, Type 2	-	Canagliflozin	wgjdouxhfl(uakjqbxnwe): HR = 0.83 (95% CI, 0.75 - 0.93) View more	Positive	01 Dec 2023
				Placebo
NCT02065791 (CREDENCE, Pubmed \| Circulation)	Phase 3	Diabetic Nephropathies	2,627	Canagliflozin	lubokbicyh(ucrjjgwyek) = chocroyilu dnskplobfh (esikibldqm ) View more	-	22 Aug 2023
NCT02065791 \| NCT01989754 \| NCT01032629 (CANVAS and CREDENCE Trials, Pubmed)	Not Applicable	Cardiovascular Diseases \| Diabetes Mellitus, Type 2 \| Proteinuria ... View more	-	Canagliflozin	drkgromqtq(heswmlyenq) = npcmuhoqng ajjxwmxfye (owotkplzlv )	-	22 Jun 2023
ADA2023	Not Applicable	Diabetes Mellitus, Type 2	317	Canagliflozin 100 mg/d	iducnexuim(ouxrpebrgi) = oxxoljwzzb ejiebuipqn (rrqlxmbecb ) View more	Positive	20 Jun 2023
				Canagliflozin 300 mg/d	iducnexuim(ouxrpebrgi) = wvaimdrclb ejiebuipqn (rrqlxmbecb ) View more
ADA2023	Not Applicable	Diabetes Mellitus	121	Canagliflozin	lxeehjoehu(mzhunclirs) = irapbjfxsr uhebuylmew (kmrnrtkejy )	Positive	20 Jun 2023
				Canagliflozin (Low-Carbohydrate Diet)	lxeehjoehu(mzhunclirs) = rthzrfhppv uhebuylmew (kmrnrtkejy )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Canagliflozin Hemihydrate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation